Stroke's next bottleneck isn't the clot. It's the cavity.

Stroke care has spent two decades getting faster at one job: reopening the artery. The harder job, replacing the tissue that died while the artery was closed, has no approved tools. The bottleneck has quietly moved from unclogging to rebuilding, and the next decade of stroke medicine will be defined by who can do the second job cheaply enough to matter.

Segura's lab at Duke, in a paper in Cell Biomaterials, is betting the contractor is already on site. The strategy is not a new drug but a porous injectable scaffold, placed in the stroke cavity five days after the attack, that recruits the body's own neutrophils and tilts them from a destructive to a reparative phenotype. New blood vessels follow, the tissue support structure reorganizes, and mice recover motor function. The five-day delay is the point: it treats repair as a separate job from rescue, not a faster version of it.

This is a research-stage result in mice, not a therapy. The clinical path is long, and several regenerative strategies compete for the same niche. But the frame the field now needs is plain: once blood flow is restored, the work has just begun. The next gains in stroke recovery will not come from a faster clot buster. They will come from rebuilding, with the immune system as contractor and timing as the design choice.